APO Research
Talk to an analyst

APO RESEARCH · REPORT

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Growth and Trends Forecast to 2032

27 December 2025105 pages

Choose your research edition.

Industry ResearchTreatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) include Tonghua Zhongsheng Pharmaceutical, Zhengzhou Taifeng Pharmaceutical, Shapuaisi Pharma, Luoxin Pharmaceutical, Zydus Pharms, Teva, Pfizer, Avet Pharmaceuticals and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market by Company

Tonghua Zhongsheng Pharmaceutical

Zhengzhou Taifeng Pharmaceutical

Shapuaisi Pharma

Luoxin Pharmaceutical

Zydus Pharms

Teva

Pfizer

Avet Pharmaceuticals

AstraZeneca

Alnylam Pharmaceuticals

Akcea Therapeutics

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment by Type

RNA Interference

Antisense Oligonucleotides

Transthyretin Tetramer Stabilizer

Other

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of RNA Interference Table 2. Major Company of Antisense Oligonucleotides Table 3. Major Company of Transthyretin Tetramer Stabilizer Table 4. Major Company of Other Table 5. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2026) & (K Units) Table 7. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Type (2021-2026) Table 8. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2026) & (US$ Million) Table 9. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Type (2021-2026) Table 10. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Price by Type (2021-2026) & (US$/Unit) Table 11. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2027-2032) & (K Units) Table 12. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Type (2027-2032) Table 13. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2027-2032) & (US$ Million) Table 14. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Type (2027-2032) Table 15. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Price by Type (2027-2032) & (US$/Unit) Table 16. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2026) & (K Units) Table 17. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2026) & (K Units) Table 19. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2026) & (K Units) Table 23. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2021-2026) & (US$ Million) Table 26. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Trends Table 27. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Drivers Table 28. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Opportunities and Challenges Table 29. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Restraints Table 30. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Company (2021-2026) Table 32. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Company (2021-2026) & (K Units) Table 33. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Share by Company (2021-2026) Table 34. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Major Company Production Sites and Headquarters Table 37. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Company, Product Type & Application Table 38. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region (2021-2026) & (K Units) Table 43. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Region (2021-2026) Table 44. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region (2021-2026) & (US$ Million) Table 45. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Region (2021-2026) Table 46. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region (2027-2032) & (K Units) Table 48. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Region (2027-2032) Table 49. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region (2027-2032) & (US$ Million) Table 50. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Region (2027-2032) Table 51. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2026) & (K Units) Table 54. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Application (2021-2026) Table 55. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2026) & (US$ Million) Table 56. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Application (2021-2026) Table 57. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Price by Application (2021-2026) & (US$/Unit) Table 58. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2027-2032) & (K Units) Table 59. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Application (2027-2032) Table 60. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2027-2032) & (US$ Million) Table 61. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Application (2027-2032) Table 62. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Price by Application (2027-2032) & (US$/Unit) Table 63. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2026) & (K Units) Table 64. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2026) & (K Units) Table 66. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2026) & (K Units) Table 70. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2021-2026) & (US$ Million) Table 73. Tonghua Zhongsheng Pharmaceutical Company Information Table 74. Tonghua Zhongsheng Pharmaceutical Business Overview Table 75. Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 77. Tonghua Zhongsheng Pharmaceutical Recent Development Table 78. Zhengzhou Taifeng Pharmaceutical Company Information Table 79. Zhengzhou Taifeng Pharmaceutical Business Overview Table 80. Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 82. Zhengzhou Taifeng Pharmaceutical Recent Development Table 83. Shapuaisi Pharma Company Information Table 84. Shapuaisi Pharma Business Overview Table 85. Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 87. Shapuaisi Pharma Recent Development Table 88. Luoxin Pharmaceutical Company Information Table 89. Luoxin Pharmaceutical Business Overview Table 90. Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 92. Luoxin Pharmaceutical Recent Development Table 93. Zydus Pharms Company Information Table 94. Zydus Pharms Business Overview Table 95. Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 97. Zydus Pharms Recent Development Table 98. Teva Company Information Table 99. Teva Business Overview Table 100. Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 102. Teva Recent Development Table 103. Pfizer Company Information Table 104. Pfizer Business Overview Table 105. Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 107. Pfizer Recent Development Table 108. Avet Pharmaceuticals Company Information Table 109. Avet Pharmaceuticals Business Overview Table 110. Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 112. Avet Pharmaceuticals Recent Development Table 113. AstraZeneca Company Information Table 114. AstraZeneca Business Overview Table 115. AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 117. AstraZeneca Recent Development Table 118. Alnylam Pharmaceuticals Company Information Table 119. Alnylam Pharmaceuticals Business Overview Table 120. Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 122. Alnylam Pharmaceuticals Recent Development Table 123. Akcea Therapeutics Company Information Table 124. Akcea Therapeutics Business Overview Table 125. Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio Table 127. Akcea Therapeutics Recent Development Table 128. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 129. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026) & (K Units) Table 130. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2021-2026) Table 131. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Forecast by Country (2027-2032) & (K Units) Table 132. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share Forecast by Country (2027-2032) Table 133. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country (2021-2026) & (US$ Million) Table 135. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share by Country (2021-2026) Table 136. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share Forecast by Country (2027-2032) Table 138. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 139. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026) & (K Units) Table 140. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2021-2026) Table 141. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Forecast by Country (2027-2032) & (K Units) Table 142. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share Forecast by Country (2027-2032) Table 143. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country (2021-2026) & (US$ Million) Table 145. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share by Country (2021-2026) Table 146. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share Forecast by Country (2027-2032) Table 148. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 149. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026) & (K Units) Table 150. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2021-2026) Table 151. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Forecast by Country (2027-2032) & (K Units) Table 152. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share Forecast by Country (2027-2032) Table 153. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country (2021-2026) & (US$ Million) Table 155. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share by Country (2021-2026) Table 156. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share Forecast by Country (2027-2032) Table 158. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 159. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026) & (K Units) Table 160. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2021-2026) Table 161. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Forecast by Country (2027-2032) & (K Units) Table 162. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share Forecast by Country (2027-2032) Table 163. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country (2021-2026) & (US$ Million) Table 165. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share by Country (2021-2026) Table 166. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share Forecast by Country (2027-2032) Table 168. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 169. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026) & (K Units) Table 170. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2021-2026) Table 171. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Forecast by Country (2027-2032) & (K Units) Table 172. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share Forecast by Country (2027-2032) Table 173. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country (2021-2026) & (US$ Million) Table 175. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share by Country (2021-2026) Table 176. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share Forecast by Country (2027-2032) Table 178. Key Raw Materials Table 179. Raw Materials Key Suppliers Table 180. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Distributors List Table 181. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Customers List Table 182. Research Programs/Design for This Report Table 183. Authors List of This Report Table 184. Secondary Sources Table 185. Primary Sources List of Figures Figure 1. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Image Figure 2. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size (2021-2032) & (US$ Million) Figure 4. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (2021-2032) & (K Units) Figure 5. RNA Interference Image Figure 6. Global RNA Interference Sales YoY Growth (2021-2032) & (K Units) Figure 7. Antisense Oligonucleotides Image Figure 8. Global Antisense Oligonucleotides Sales YoY Growth (2021-2032) & (K Units) Figure 9. Transthyretin Tetramer Stabilizer Image Figure 10. Global Transthyretin Tetramer Stabilizer Sales YoY Growth (2021-2032) & (K Units) Figure 11. Other Image Figure 12. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share by Type 2025 VS 2032 Figure 15. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Type in 2025 Figure 16. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Type in 2025 Figure 17. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Type in 2025 Figure 18. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Type in 2025 Figure 21. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital and Clinic Image Figure 28. Global Hospital and Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 29. Retail Pharmacies Image Figure 30. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share by Application 2025 VS 2032 Figure 35. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Application in 2025 Figure 36. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Application in 2025 Figure 37. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Application in 2025 Figure 38. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Application in 2025 Figure 41. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share in Value by Application in 2025 Figure 45. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • RNA Interference
  • Antisense Oligonucleotides
  • Transthyretin Tetramer Stabilizer
  • Other
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Tonghua Zhongsheng Pharmaceutical
  • Zhengzhou Taifeng Pharmaceutical
  • Shapuaisi Pharma
  • Luoxin Pharmaceutical
  • Zydus Pharms
  • Teva
  • Pfizer
  • Avet Pharmaceuticals
  • AstraZeneca
  • Alnylam Pharmaceuticals
  • Akcea Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market by Type
  6. 1.3.1 RNA Interference
  7. 1.3.2 Antisense Oligonucleotides
  8. 1.3.3 Transthyretin Tetramer Stabilizer
  9. 1.3.4 Other
  10. 1.4 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Type
  11. 1.4.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Trends
  2. 2.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Drivers
  3. 2.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Opportunities and Challenges
  4. 2.4 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue (2021-2026)
  2. 3.2 Global Top Players by Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (2021-2026)
  3. 3.3 Global Top Players by Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Price (2021-2026)
  4. 3.4 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Major Company Production Sites & Headquarters
  6. 3.6 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Company, Product Type & Application
  7. 3.7 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Tier 1, Tier 2, and Tier 3
4 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Regional Status and Outlook
  1. 4.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Historic Market Size by Region
  3. 4.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Forecasted Market Size by Region
  7. 4.3.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Application
  1. 5.1 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market by Application
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Application
  6. 5.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Tonghua Zhongsheng Pharmaceutical
  2. 6.1.1 Tonghua Zhongsheng Pharmaceutical Company Information
  3. 6.1.2 Tonghua Zhongsheng Pharmaceutical Business Overview
  4. 6.1.3 Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  6. 6.1.5 Tonghua Zhongsheng Pharmaceutical Recent Developments
  7. 6.2 Zhengzhou Taifeng Pharmaceutical
  8. 6.2.1 Zhengzhou Taifeng Pharmaceutical Company Information
  9. 6.2.2 Zhengzhou Taifeng Pharmaceutical Business Overview
  10. 6.2.3 Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  12. 6.2.5 Zhengzhou Taifeng Pharmaceutical Recent Developments
  13. 6.3 Shapuaisi Pharma
  14. 6.3.1 Shapuaisi Pharma Company Information
  15. 6.3.2 Shapuaisi Pharma Business Overview
  16. 6.3.3 Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  18. 6.3.5 Shapuaisi Pharma Recent Developments
  19. 6.4 Luoxin Pharmaceutical
  20. 6.4.1 Luoxin Pharmaceutical Company Information
  21. 6.4.2 Luoxin Pharmaceutical Business Overview
  22. 6.4.3 Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  24. 6.4.5 Luoxin Pharmaceutical Recent Developments
  25. 6.5 Zydus Pharms
  26. 6.5.1 Zydus Pharms Company Information
  27. 6.5.2 Zydus Pharms Business Overview
  28. 6.5.3 Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  30. 6.5.5 Zydus Pharms Recent Developments
  31. 6.6 Teva
  32. 6.6.1 Teva Company Information
  33. 6.6.2 Teva Business Overview
  34. 6.6.3 Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  36. 6.6.5 Teva Recent Developments
  37. 6.7 Pfizer
  38. 6.7.1 Pfizer Company Information
  39. 6.7.2 Pfizer Business Overview
  40. 6.7.3 Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  42. 6.7.5 Pfizer Recent Developments
  43. 6.8 Avet Pharmaceuticals
  44. 6.8.1 Avet Pharmaceuticals Company Information
  45. 6.8.2 Avet Pharmaceuticals Business Overview
  46. 6.8.3 Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  48. 6.8.5 Avet Pharmaceuticals Recent Developments
  49. 6.9 AstraZeneca
  50. 6.9.1 AstraZeneca Company Information
  51. 6.9.2 AstraZeneca Business Overview
  52. 6.9.3 AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  54. 6.9.5 AstraZeneca Recent Developments
  55. 6.10 Alnylam Pharmaceuticals
  56. 6.10.1 Alnylam Pharmaceuticals Company Information
  57. 6.10.2 Alnylam Pharmaceuticals Business Overview
  58. 6.10.3 Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  60. 6.10.5 Alnylam Pharmaceuticals Recent Developments
  61. 6.11 Akcea Therapeutics
  62. 6.11.1 Akcea Therapeutics Company Information
  63. 6.11.2 Akcea Therapeutics Business Overview
  64. 6.11.3 Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolio
  66. 6.11.5 Akcea Therapeutics Recent Developments
7 North America by Country
  1. 7.1 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country
  2. 7.1.1 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026)
  4. 7.1.3 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Forecast by Country (2027-2032)
  5. 7.2 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country
  6. 7.2.1 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country (2021-2026)
  8. 7.2.3 North America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country
  2. 8.1.1 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026)
  4. 8.1.3 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country
  6. 8.2.1 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country (2021-2026)
  8. 8.2.3 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country
  2. 9.1.1 Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country
  6. 9.2.1 Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country
  2. 10.1.1 South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026)
  4. 10.1.3 South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Forecast by Country (2027-2032)
  5. 10.2 South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country
  6. 10.2.1 South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country (2021-2026)
  8. 10.2.3 South America Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country
  2. 11.1.1 Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country
  6. 11.2.1 Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Value Chain Analysis
  2. 12.1.1 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Production Mode & Process
  7. 12.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Distributors
  10. 12.2.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst